Seqirus Demerger And Cost Savings Will Shape A Steady Long Term Outlook

Catalysts

About CSL

CSL is a global biopharmaceutical group focused on plasma therapies, vaccines and specialty medicines addressing rare and serious diseases.

What are the underlying business or industry changes driving this perspective?

• The planned demerger of CSL Seqirus into a separately listed entity in financial year 2026 is expected to simplify each business and allow sharper capital allocation, which could support steadier revenue growth and more focused earnings delivery in each unit.
• The multiyear transformation program targeting more than US$0.5b in annual pretax savings by the end of financial year 2028, combined with the intention to reinvest roughly half of these funds, is set up to affect both net margins and longer term earnings, depending on how effectively costs are removed and redirected.
• Rollout of the RIKA plasmapheresis system and iNomi platform across the plasma network, along with 22 U.S. center closures, is expected to lift plasma collection efficiency and lower cost per liter over time, which directly influences CSL Behring gross margin and, by extension, group operating margin.
• Growth initiatives in higher value therapies such as HIZENTRA, ANDEMBRY and HEMGENIX, alongside label expansion work for KCENTRA and RiaSTAP, point to a mix shift toward products with stronger economics. The impact is likely to be most visible in revenue per unit and operating margin rather than pure volume growth.
• CSL Vifor’s continued push into iron and nephrology, including Ferinject expansion in China and broader international markets and ongoing launches of TAVNEOS and FILSPARI, reflects long term demand for chronic kidney and iron deficiency treatments. The main financial impact is expected in segment revenue and return on invested capital as new geographies scale.

Assumptions

This narrative explores a more pessimistic perspective on CSL compared to the consensus, based on a Fair Value that aligns with the bearish cohort of analysts. How have these above catalysts been quantified?

• The bearish analysts are assuming CSL's revenue will grow by 2.9% annually over the next 3 years.
• The bearish analysts assume that profit margins will increase from 19.3% today to 22.1% in 3 years time.
• The bearish analysts expect earnings to reach $3.7 billion (and earnings per share of $7.86) by about February 2029, up from $3.0 billion today. However, there is some disagreement amongst the analysts with the more bullish ones expecting earnings as high as $4.5 billion.
• In order for the above numbers to justify the price target of the more bearish analyst cohort, the company would need to trade at a PE ratio of 20.2x on those 2029 earnings, which is the same as it is today today. This future PE is about the same as the current PE for the AU Biotechs industry at 20.2x.
• The bearish analysts expect the number of shares outstanding to remain consistent over the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 7.2%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

• Management is targeting annual pretax savings of more than US$0.5b by the end of financial year 2028, with around half earmarked for reinvestment into earlier stage R&D, clinical programs and commercial initiatives. This may support higher long term revenue growth and earnings than implied by a flat share price view, especially if those projects translate into new therapies or indications that scale well in core franchises, lifting revenue and earnings.
• The company has guided to CSL Behring gross margin moving back toward historical highs over time, supported by yield gains, the full rollout of the RIKA and iNomi platforms, closure of 22 underperforming centers and mix shift toward higher margin products like HIZENTRA and ANDEMBRY. If delivered, this could create steady margin expansion and support stronger earnings growth than a “no-change” share price assumption implies, directly affecting gross margin and net margins.
• Management expects continued robust demand for immunoglobulin, hereditary angioedema therapies, hemophilia products and nephrology and iron treatments, with several products such as HEMGENIX, ANDEMBRY, TAVNEOS, FILSPARI and Ferinject expanding across geographies and indications. If this long term demand plays through as described it could sustain multi year revenue growth that contradicts the expectation of a broadly flat share price, with the main impact on revenue and operating earnings.
• The planned demerger of CSL Seqirus into a separate ASX listed company is intended to reduce complexity and allow each business to focus on its core capabilities. The group also runs a multiyear on market share buyback within a 1.5x to 2x net debt to EBITDA leverage range, and if these changes lead to more efficient capital allocation, stronger returns on invested capital and higher earnings per share, the share price may not remain static, affecting earnings per share and return on invested capital.
• Management commentary points to attractive fundamentals in key disease areas, positive long term outlooks in seasonal influenza and chronic kidney and iron deficiency markets, and a company level goal to deliver double digit earnings growth over the medium term. If these long horizon trends are reflected in sustained NPAT and NPATA growth, the valuation the market is willing to pay, such as the P/E multiple, could rise or at least hold up better than a flat share price view assumes, impacting earnings and the implied P/E.

Valuation

How have all the factors above been brought together to estimate a fair value?

• The assumed bearish price target for CSL is A$180.87, which represents up to two standard deviations below the consensus price target of A$231.2. This valuation is based on what can be assumed as the expectations of CSL's future earnings growth, profit margins and other risk factors from analysts on the more bearish end of the spectrum.
  
• However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of A$283.17, and the most bearish reporting a price target of just A$180.87.
  
• In order for you to agree with the more bearish analyst cohort, you'd need to believe that by 2029, revenues will be $16.9 billion, earnings will come to $3.7 billion, and it would be trading on a PE ratio of 20.2x, assuming you use a discount rate of 7.2%.
  
• Given the current share price of A$180.5, the analyst price target of A$180.87 is 0.2% higher. The relatively low difference between the current share price and the analyst consensus price target indicates that they believe on average, the company is fairly priced.
  
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.